Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (71)	9/13/2000 11:42:51 PM
From: tommysdad	Read Replies (1) \| Respond to of 598

Tuck, TLRK is concentrating on orphan nuclear receptors. SNAP's expertise is orphan GPCRs (G-protein coupled receptors). Thus SNAP is not a direct competitor of TLRK's programs. X-Ceptor certainly is a direct competitor. Glaxo has a very strong nuclear orphan program. Signal was playing in that area for awhile, but I think they got out (and whoever bought them -- Celgene? -- would certainly squash whatever may be left). That's about it, I think.